MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Ascierto, Paolo A, MD, Schadendorf, Dirk, Prof, Berking, Carola, Prof, Agarwala, Sanjiv S, Prof, van Herpen, Carla ML, MD, Queirolo, Paola, MD, Blank, Christian U, MD, Hauschild, Axel, Prof, Beck, J Thaddeus, MD, St-Pierre, Annie, PhD, Niazi, Faiz, MPharm, Wandel, Simon, PhD, Peters, Malte, MD, Zubel, Angela, MD, Dummer, Reinhard, Prof
Published in The lancet oncology (01.03.2013)
Published in The lancet oncology (01.03.2013)
Get full text
Journal Article